
Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act
10/23/2026
0:00
2:37
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.
More episodes from "Pharmaceutical Executive"



Don't miss an episode of “Pharmaceutical Executive” and subscribe to it in the GetPodcast app.








